SCHEMBL10003500

SCHEMBL10003500

CCc1nc2c(cc1-c1ccc(OC)cc1)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 4/20 0.41
▸ GRIA2 P42262 3/20 0.40
▸ GRIA4 P48058 3/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ PTGS1 P23219 1/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ NT5E P21589 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ PTGER1 P34995 2/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ PRKAB2 O43741 1/20 0.35
▸ PRKAG1 P54619 1/20 0.35
▸ PRKAA2 P54646 1/20 0.35
▸ PRKAA1 Q13131 1/20 0.35
▸ PRKAG3 Q9UGI9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003244 0.90 PTPN11 (0.39) PTPN11PTGDR2PTGS2SCN9A
SCHEMBL10002905 0.90 GRIA2 (0.38) GRIA2GRIA4SMN1; SMN2ALDH1A1SCN9A
SCHEMBL10003383 0.90 ALPI (0.35) PTGS1PTGS2SCN9A
SCHEMBL10003409 0.90 GRIA2 (0.36) GRIA2GRIA4KDM4EALDH1A1PTGER1
SCHEMBL10003096 0.90 GRIA2 (0.35) GRIA2GRIA4PTGDR2SMN1; SMN2KDM4E
SCHEMBL10003313 0.90 PRKAB2 (0.37) PTPN11PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL10003394 0.90 GRIA2 (0.43) PTPN11GRIA2GRIA4PTGS2SMN1; SMN2
SCHEMBL12003592 0.90 POLB (0.42) PTPN11PTGS1PTGS2SMN1; SMN2KDM4E
SCHEMBL10003970 0.90 GRIA2 (0.37) GRIA2GRIA4PTGDR2SMN1; SMN2KDM4E
SCHEMBL10003810 0.89 PIK3CA (0.45) PTGS1PTGS2SCN9APRKAG1PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH PTPN11 741/4885GRIA2 3298/4885GRIA4 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback